Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

NSAID/triptan combination improves treatment-resistant migraine

Publish date:: June 18, 2020

Key clinical point: The NSAID/triptan combination could be best suited for patients who have failed acute treatments.

Major finding: The combination outperformed rizatriptan alone with respect to 1-hour pain relief (44% vs. 37%) and 2- to 24-hour sustained pain relief (53% vs. 44%).

Study details: Randomized, controlled trial (n = 1,594).

Disclosures: The study was funded by Axsome Therapeutics. Dr. O’Gorman is an employee of Axsome.

Citation:

O’Gorman C et al. AHS 2020, Abstract 840673.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Headache & Migraine

HIT-6 may help track meaningful change in chronic migraine,

Choroid plexuses may play a role in migraine,

Multiple traits more common in difficult-to-treat patients with migraine,

Marijuana for migraine? Some tentative evidence,

Low vitamin D levels in patients with migraine,